Global Knee Denervation Market Strategic Research Report

Scope of the Report

The global Knee Denervation market size is predicted to grow from US$ 425 million in 2025 to US$ 1,489 million in 2032; it is expected to grow at a CAGR of 19.8% from 2026 to 2032.

Knee denervation is a minimally invasive medical procedure designed to reduce chronic knee pain, typically in patients with osteoarthritis or persistent pain following knee surgeries, such as knee replacements. The procedure involves selectively interrupting the sensory nerves that transmit pain signals from the knee to the brain. This is achieved without affecting motor function, thereby preserving joint movement.

Osteoarthritis (OA) is a degenerative disease common in synovial joints, which can cause degeneration of articular cartilage, bone hyperplasia at the joint margin and under the cartilage, etc. Knee osteoarthritis (KOA) is the most common knee disease in the limb joints. Domestic statistics show that more than 3% of people in my country suffer from OA, and KOA accounts for the majority. As my country gradually enters an aging society, the incidence of KOA is higher in the population. According to relevant data, the incidence rate in people over 60 years old is as high as 12%, and it is increasing with age.

KOA is essentially a degenerative disease and cannot be cured clinically. At present, KOA patients mostly use conservative treatments such as physical therapy, analgesics and intra-articular injections to control pain and improve their quality of life. Before drug intervention, there are auxiliary treatment measures such as physical therapy, exercise, and weight loss. It is generally believed that anti-inflammatory analgesics are the first choice for the treatment of KOA, but long-term use often produces adverse reactions. Intra-articular injection of glucocorticoids or sodium hyaluronate is believed to relieve inflammation in the joint and promote cartilage repair. Repeated injections can maintain the efficacy, but the effect will still decline after several years. Total knee arthroplasty (TKA) surgery is considered to be the only effective ultimate solution, but some patients still have poor postoperative effects or long-term postoperative pain. The urgent need for pain treatment in KOA patients has given rise to the application of Knee Denervation technology in this field.

Knee Denervation includes traditional radiofrequency ablation (RFA), pulsed radiofrequency (PRF), cooled RFA (CRF) and laser treatment. The principles, parameters and efficacy of Knee Denervation technology are still in the early stages, which leads to large differences in the technical methods used by different research teams. However, through a systematic evaluation of numerous clinical trials and case reports, it can still be concluded that Knee Denervation can relieve pain and improve quality of life for up to about 1 year in the treatment of postoperative pain after KOA or TKA, and has the advantages of less trauma and fewer complications.

According to our data, the global volume of Knee Denervation surgeries will be around 130,000 in 2024, and the volume is expected to reach 155,000 in 2025. The compound annual growth rate of Knee Denervation will reach more than 15% in the next five years, and the market size will exceed US$100 million by 2030. From a regional perspective, North America occupies a major position in the Knee Denervation industry with its complete medical facilities and advanced technology, with a market share of nearly 50% in 2024, followed by Europe and Asia Pacific. From a technical point of view, the main method of Knee Denervation is radiofrequency ablation, which will account for more than 90% in 2024, but laser therapy (invasive LA) and other methods are gradually showing their advantages and are developing rapidly.

With the extension of life expectancy, the health problems caused by degenerative diseases will inevitably become a major health threat. The knee joint is an important load-bearing joint in the human body. Chronic pain, especially KOA, will seriously reduce the quality of life of patients. Patients with moderate to severe or refractory KOA benefit less from traditional treatments and have to endure many adverse reactions. TKA surgery can only solve the problems of some patients. Some patients still have poor surgical results or do not have the conditions for surgical treatment. Knee Denervation for pain treatment has shown good therapeutic effects and high safety, and has huge market potential in the future.

This report presents a comprehensive overview of the global Knee Denervation market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Standard RFA
• Cooled RFA
• Others

Segment by Application

• Hospital
• Clinic

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Knee Denervation market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Clinic evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact